PRLD - Prelude Therapeutics Incorporated
About Prelude Therapeutics Incorporated (https://www.preludetx.com)
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Krishna Vaddi | Founder, Chief Executive Officer & Director | 1966 | $935,256 USD |
| Bryant David Lim | Chief Financial Officer, Chief Legal Officer & Corporate Secretary | 1971 | $681,050 USD |
| Peggy A. Scherle | Chief Scientific Officer | 1962 | $674,206 USD |
| Andrew Combs | Executive Vice President & Chief Chemistry Officer | 1967 | $562,461 USD |
| Aimee Crombie | Senior Vice President and Head of Strategic Planning & Operations | – | – |
| Madhu Pudipeddi | Senior Vice President of Technical Operations | – | – |
| Michele Porreca | Chief People Officer | – | – |
| Naveen Babbar | Senior Vice President of Translation Medicine | – | – |
| Robert A. Doody Jr. | Senior Vice President of Investor Relations | – | – |
| Wan-Jen Hong | Senior Vice President of Clinical Development | 1979 | – |